PCT 2017

From 79 to 1: Bayer says PRA partnership eases ‘administrative burden’

By Flora Southey contact

- Last updated on GMT

GettyImages/MissTun
GettyImages/MissTun

Related tags: Pra health sciences, Contract research organization, Clinical trial

Transitioning to a single strategic contract research organization (CRO) reduced Bayer’s administrative burden, but the restructuring was met with some resistance, said the firm.

Bayer – which runs 50% of its clinical studies in-house – selected PRA Health Sciences to be its preferred partner for in-house clinical development worldwide in September 2014 to consolidate and simplify its resource spending in trials, said Bayer’s Keith Francis.

“We started with more than 40 countries and 79 suppliers,” ​Francis told delegates at the Partnerships in Clinical Trials (PCT) conference in Amsterdam last week.

“We ended up with a high administrative burden – with 79 suppliers, you can imagine the number of contracts that needed to be managed and reviewed, and invoices for payments,” ​said Francis, adding that those vendors are now completely out of the picture.

Although PRA Health Sciences is Bayer’s preferred partner for in-house operations, PRA’s director of clinical operations Chris Eastwood told delegates it supports Bayer with approximately 98 to 99% of its requirements.

Other vendors have been retained in a couple remote locations, so strictly speaking, it is not entirely an exclusive agreement, said Eastwood.

Resisting change

According to Francis, Bayer did experience some resistance from vendors when transitioning to a single, strategic partnership with PRA. 

“Certainly there was some resistance at first, for a variety of reasons,” ​he told delegates. “In many countries, they had established relationships with local providers, which was something they didn’t want us to dismantle.”

From a country perspective, these vendors may not have perceived the arrangement as administratively inefficient, but from a global perspective, we needed to show what more we could do by simplifying operations, he said.

Related news

Related products

show more

Next generation ePRO from SQN Health

Next generation ePRO from SQN Health

In an era of rapid technology growth, healthcare requires low cost solutions for real-time data collection. We have come a long way from paper to EDC and...

baxter_bloomington_facility_larger

Sterile Injectables Contract Manufacturing

Baxter BioPharma Solutions | 02-Apr-2018 | Product Brochure

Baxter BioPharma Solutions' award-winning facility in Bloomington, Indiana, USA, is a leader in sterile contract manufacturing of injectable products.

Related suppliers

Follow us

Products

View more